These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 15159322)

  • 1. Predictors of participation in psychosocial telephone counseling following genetic testing for BRCA1 and BRCA2 mutations.
    Halbert CH; Wenzel L; Lerman C; Peshkin BN; Narod S; Marcus A; Corio C; Demarco T; Bellamy S
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):875-81. PubMed ID: 15159322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
    Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
    JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
    CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing.
    Lerman C; Hughes C; Lemon SJ; Main D; Snyder C; Durham C; Narod S; Lynch HT
    J Clin Oncol; 1998 May; 16(5):1650-4. PubMed ID: 9586874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial.
    Kinney AY; Butler KM; Schwartz MD; Mandelblatt JS; Boucher KM; Pappas LM; Gammon A; Kohlmann W; Edwards SL; Stroup AM; Buys SS; Flores KG; Campo RA
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25376862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers.
    Graves KD; Wenzel L; Schwartz MD; Luta G; Wileyto P; Narod S; Peshkin BN; Marcus A; Cella D; Emsbo SP; Barnes D; Halbert CH
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):648-54. PubMed ID: 20200423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?
    Maheu C; Bouhnik AD; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Lasset C; Berthet P; Fricker JP; Caron O; Luporsi E; Gladieff L; Julian-Reynier C
    Psychooncology; 2014 Apr; 23(4):420-7. PubMed ID: 24127257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
    Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The decision to test in women receiving genetic counseling for BRCA1 and BRCA2 mutations.
    Kelly K; Leventhal H; Andrykowski M; Toppmeyer D; Much J; Dermody J; Marvin M; Baran J; Schwalb M
    J Genet Couns; 2004 Jun; 13(3):237-57. PubMed ID: 15604634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
    DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
    Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
    Armstrong K; Micco E; Carney A; Stopfer J; Putt M
    JAMA; 2005 Apr; 293(14):1729-36. PubMed ID: 15827311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
    Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
    Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
    J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing.
    McKinnon W; Naud S; Ashikaga T; Colletti R; Wood M
    J Genet Couns; 2007 Aug; 16(4):433-56. PubMed ID: 17594133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.